Viral hepatitis is an inflammation of the liver caused by a virus. The most common hepatitis viruses in Europe are types A, B, and C (commonly referred to as HAV, HBV and HCV).
This update reports on one of the ECDC multi-country studies that is centred around the hospital setting and severe disease, with the aim of assessing vaccine effectiveness against severe acuterespiratory infection (SARI) due to laboratory-confirmed SARS-CoV-2 within the ECDC VaccineEffectiveness, Burden and Impact Studies infrastructure (VEBIS) [1,2].
ECDC, HERA, and DG SANTE have agreed to strengthen cooperation and to coordinate their work in support of health emergency preparedness and response in the area of medical countermeasures.